Recently we demonstrated that PLC⑀ plays an important role in ␤-adrenergic receptor (␤AR) stimulation of Ca
2؉
-induced Ca 2؉ release (CICR) in cardiac myocytes. Here we have reported for the first time that a pathway downstream of ␤AR involving the cAMPdependent Rap GTP exchange factor, Epac, and PLC⑀ regulates CICR in cardiac myocytes. To demonstrate a role for Epac in the stimulation of CICR, cardiac myocytes were treated with an Epacselective cAMP analog, 8-4-(chlorophenylthio)-2-O-methyladenosine-3,5-monophosphate (cpTOME). cpTOME treatment increased the amplitude of electrically evoked Ca 2؉ transients, implicating Epac for the first time in cardiac CICR. This response is abolished in PLC⑀ ؊/؊ cardiac myocytes but rescued by transduction with PLC⑀, indicating that Epac is upstream of PLC⑀. Furthermore, transduction of PLC⑀ ؉/؉ cardiac myocytes with a Rap inhibitor, RapGAP1, significantly inhibited isoproterenol-dependent CICR. Using a combination of cpTOME and PKA-selective activators and inhibitors, we have shown that ␤AR-dependent increases in CICR consist of two independent components mediated by PKA and the novel Epac/PLC⑀ pathway. We also show that Epac/PLC⑀-dependent effects on CICR are independent of sarcoplasmic reticulum loading and Ca 2؉ clearance mechanisms. These data define a novel endogenous PKA-independent ␤AR-signaling pathway through cAMP-dependent Epac activation, Rap, and PLC⑀ that enhances intracellular Ca 2؉ release in cardiac myocytes.
Stimulation of adrenergic receptors by either neurohumoral or systemic release of the catecholamines epinephrine and norepinephrine produces acute increases in cardiac contractility during stress and exercise to increase cardiac output and oxygen delivery to tissues. Much of the increase in cardiac output is due to the direct stimulation of the ␤ adrenergic receptor (␤AR) 2 in cardiac myocytes (1, 2) . Activation of ␤AR activates G s and adenylyl cyclase resulting in the production of cAMP and subsequent activation of protein kinase A, which phosphorylates key components of the calcium handling and contractile machinery.
Analysis of a phospholipase C (PLC)⑀ knock-out mouse model (PLC⑀ Ϫ/Ϫ ) generated in our laboratory indicates that PLC⑀ contributes to ␤AR-dependent regulation of cardiac function (3) . PLC⑀ Ϫ/Ϫ mice exhibit significantly decreased left ventricular developed pressure in response to acute stimulation with the ␤AR agonist, isoproterenol. Isolated myocytes from PLC⑀ Ϫ/Ϫ mice exhibit decreased isoproterenol-dependent enhancement of electrically evoked Ca 2ϩ release in the absence of effects on ␤AR density or cAMP generation. These data implicate PLC⑀ as a novel component of ␤AR regulation of Ca 2ϩ release, which had not previously been described in the heart. However, the pathway linking ␤AR stimulation to PLC⑀ activation is unknown.
PLC-mediated phosphatidyl-4,5-bisphosphate hydrolysis resulting in intracellular Ca 2ϩ release and protein kinase C activation is an integral signaling component of many physiological processes in a variety of tissues, including the cardiovascular system (4, 5) . PLC⑀ is a recently identified PLC isoform expressed in the heart as well as other tissues (6 -8) . A particularly unique feature of this enzyme is direct regulation of its phosphatidyl-4,5-bisphosphate hydrolysis activity by Ras and Ras family members including Rap (6, 8 -11) . In addition, PLC⑀ has guanine nucleotide exchange factor activity and can activate small G proteins such as Rap1 (12) . Thus, PLC⑀ is uniquely positioned to respond to multiple receptor inputs in the heart and coordinate both PLC and guanine nucleotide exchange factor activities that could be important for cardiac function.
Here we have demonstrated for the first time a new pathway involving PLC⑀ and the cAMP-responsive Rap guanine nucleotide exchange factor, Epac, in adult ventricular car-* This work was supported by National Institutes of Health Grants GM053536 (to A. V. S.), DK56294 (to G. G. K.), and AR44657 (to R. T. D.), an American Heart Association Scientist Development grant (to B. C. B.), and Oral Cellular and Molecular Biology Training Grant T32 DE07202-15 (to E. A. O.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 (13) and has been shown to activate PLC⑀ in a Rapdependent manner (14) . We show here that cAMP-stimulated Epac/Rap1-dependent activation of PLC⑀ acts in concert with the classical cAMP-dependent activation of PKA to facilitate ␤AR-mediated enhancement of intracellular Ca 2ϩ release from the sarcoplasmic reticulum in cardiac myocytes. This novel pathway introduces a new level of regulation of cardiac function by the ␤AR system and is likely to have implications for the treatment of cardiac disease.
EXPERIMENTAL PROCEDURES
Isolation of Adult Ventricular Cardiac Myocytes-Adult ventricular cardiac myocytes (AVMs) were isolated from 4-monthold wild-type or PLC⑀ Ϫ/Ϫ mice as previously described (3). Mice were anesthetized with ketamine (100 mg/kg body weight) and xylazine (5 mg/kg body weight) by intraperitoneal injection. For all experiments, cells were plated at a density of 10,000 cells/35-mm dish on laminin (BD Biosciences)-coated coverslips in minimum essential medium supplemented with 2 mM L-glutamine, 2.5% fetal bovine serum (Hyclone), and 1% penicillin/streptomycin with the addition of 1 M Blebbistatin (Sigma) to prevent spontaneous contraction. Pharmacological Manipulation of Epac and PKA-For Epac activation, after data were collected in the absence of agonist, cells were constantly perfused with 10 M cpTOME (Calbiochem) for 20 s followed by a 60-s train of electrical stimuli at 1 Hz. The change in 405/485 ratio was determined for 10 -20 cells/animal. For PKA activation, cells were pretreated for 30 min with 300 M 6-Bnz-cAMP (Axxora, LLC San Diego, CA) during Indo-1/AM loading and data were then collected as previously described. 300 M 6-Bnz-cAMP was present throughout the experiment. For PKA inhibition, cells were treated with 10 M H89 (Calbiochem) alone prior to perfusion with 1 M isoproterenol. H89 was present throughout perfusion. For inhibition of PKA-specific responses, cells were pretreated with 10 M H89 plus 300 M 6-Bnz-cAMP for 30 min followed by constant perfusion with 300 M 6-Bnz-cAMP. Alternatively, cells were pretreated for 30 min with a combination of 350 M Rp-cAMPs and 8-Br-Rp-cAMPs (Axxora) to assess PKA inhibition. Data were collected as previously.
Measurement of Electrically Evoked
Transduction of Cardiac Myocytes with Adenovirus-Adenoviruses were prepared using the AdEasy system with the cytomegalovirus promoter used to drive expression of either yellow fluorescent protein (YFP) or FLAG-PLC⑀. Adult AVMs were isolated and adhered to laminin-coated coverslips for 2 h preinfection. The plating medium was then removed and replaced with fresh medium containing 300 m.o.i. of either YFP control, PLC⑀, or RapGAP1 adenovirus. RapGAP1 adenovirus was kindly provided by Dr. Patrick Casey, Duke University (15). After 2 h, the virus was removed, and fresh medium was added to the cells. PLC⑀ expression was not detectable by direct Western analysis at 24 h but was detectable at 48 h. PCR analysis described below was used to detect PLC⑀ expression at 24 h. Because endogenous PLC⑀ was comparable with adenovirally expressed PLC⑀ at 24 h (based on reverse transcription (RT)-PCR analysis), experiments were performed 24 h post-infection to minimize PLC⑀ overexpression and more closely mimic endogenous expression levels. For Rap dominant negative inhibition, myocytes were infected with an adenovirus-expressing RapGAP1 driven by a cytomegalovirus promoter. Cells were analyzed 48 h post-infection to maximize both RapGAP1 overexpression and Rap inhibition. Indo-1/AM fluorescence ratio (405/485) was assessed as previously Ϯ1 M isoproterenol or Ϯ10 M cpTOME. Myocytes were electrically stimulated at 0.5 Hz in all experiments with adenovirally infected AVMs.
Immunoblotting-For Epac and Rap1 expression level comparisons, tissue lysates were prepared from hearts excised from 4-month-old wild-type and PLC⑀ Ϫ/Ϫ mice. To assess expression of proteins by adenovirus and expression levels of PKA subunits, AVM cell lysates were prepared. Proteins were resolved by standard SDS-PAGE and transferred to nitrocellulose membranes (Bio-Rad) for blotting. Epac rabbit polyclonal antibody (used at 1:1000) was from Upstate Biotechnology, Rap1 and Rap1GAP rabbit polyclonal antibodies (used at 1:200) were from Santa Cruz Biotechnology, and PKA mouse monoclonal antibodies (used at 1:1000) were from BD Transduction Laboratories. PLC⑀ rabbit polyclonal antibody was kindly provided by Dr. Grant Kelley, SUNY Upstate Medical University (used at 1:3000). G protein ␤-subunit rabbit polyclonal antibody, B600 (16) , was used at 1:40,000.
RT-PCR-For detection of PLC⑀ mRNA in PLC⑀ ϩ/ϩ , PLC⑀ Ϫ/Ϫ , and PLC⑀ Ϫ/Ϫ AVMs transduced with FLAG-PLC⑀-expressing adenovirus (300 m.o.i., 10,000 cells), RNA was prepared using the RNAeasy minikit (Qiagen, Inc., Valencia, CA) following the recommendations of the manufacturer. The Superscript III RT-PCR kit (Invitrogen) was used with 150 ng of total RNA template for RT-PCR reactions with the mouse PLC⑀ primers 5Ј-ACCCTGCGGTAAATGTTCTG-3Ј and 5Ј-ATG-TGAATTCCGTGCTACCC-3Ј to give a predicted 300-bp product. GAPDH primers 5Ј-CAACGGGAAGCCCATC-ACCAT-3Ј and 5Ј-CCTTGGCAGCACCAGTGGATGC-3Ј yielded a predicted 350-bp product. RT was done for 30 min at 42°C followed by incubation at 94°C for 2 min. The PCR parameters were denaturation at 94°C for 30 s, annealing at 45°C for 45 s., and extension at 72°C. The number of PCR cycles was 23, 26, and 30 for GAPDH and 30, 32, and 35 for PLC⑀.
RESULTS
We recently reported a significant decrease in ␤-adrenergic receptor-dependent enhancement of electrically evoked Ca 2ϩ release in ventricular myocytes isolated from PLC⑀ Ϫ/Ϫ mice (3) and hypothesized that PLC⑀ plays a direct role in the ␤AR-signaling cascade. PLC activation as a result of ␤AR stimulation in the heart has not been previously described. A potential pathway from the ␤AR to PLC⑀ demonstrated in human embryonic kidney 293 fibroblasts involves stimulation of G S , elevation of cAMP, activation of Epac, increased guanine nucleotide exchange on Rap, and subsequent PLC⑀ activation (14) . To investigate whether this pathway operates in cardiac myocytes, we utilized cpTOME, a cAMP analog with preferential specificity for Epac activation (17) . In freshly isolated AVMs, electrically evoked Ca 2ϩ transients were assessed in the presence and absence of 10 M cpTOME. Surprisingly, cpTOME treatment alone increased the magnitude of electrically stimulated Ca 2ϩ transients ϳ2-fold (Fig. 1, A and B) in PLC⑀ ϩ/ϩ myocytes. Strikingly, however, cpTOME did not effect electrically evoked Ca 2ϩ release in PLC⑀ Ϫ/Ϫ myocytes (Fig. 1, A and B) , supporting the idea that Epac acts upstream of PLC⑀. Western blotting confirmed that Epac and Rap expression are not significantly altered in heart tissue from PLC⑀ Ϫ/Ϫ mice (Fig. 1C ). To provide further evidence for involvement of PLC⑀ in Epac regulation of CICR, PLC⑀ was re-introduced into PLC⑀ Ϫ/Ϫ myocytes by adenoviral transduction. PLC⑀ mRNA was detected by semiquantitative RT-PCR at levels similar to PLC⑀ ϩ/ϩ AVMs after 24 h of adenoviral infection (Fig. 1D ), but at this point, adenovirally expressed PLC⑀ protein was not reliably detectable by immunoblotting. In general, this 250-kDa protein does not express to high levels even with adenoviral transduction. PLC⑀ protein was detectable at 48 h (Fig. 1E) , demonstrating that PLC⑀ protein is expressed by this virus in AVMs. We chose to assay myocyte function 24 h post-infection to more closely mimic low endogenous levels of PLC⑀ expression. The cpTOME-induced increase in Ca 2ϩ transient amplitude was completely rescued by re-introduction of PLC⑀ into PLC⑀ Ϫ/Ϫ myocytes (Fig. 1F) . Together, these data indicate that an Epac-PLC⑀ pathway exists in cardiac myocytes to regulate CICR that is activated by cAMP downstream of ␤AR stimulation.
Because the primary function of Epac is to act as a guanine nucleotide exchange factor for Rap GTPases and Rap is a known activator of PLC⑀, we hypothesized that Rap activation is required for maximal enhancement of Ca 2ϩ release following ␤AR stimulation. To implicate Rap in the ␤AR pathway, we transduced wild-type AVMs with an adenovirus-encoding expression of RapGAP1 ( Fig. 2A) , a protein that accelerates GTP hydrolysis on activated Rap1, returning Rap1 to its GDP-bound inactive state (18) . Expression of RapGAP1 has been used to inhibit Rap1 and implicate Rap function in a number of systems (15, 19, 20) . Wild-type myocytes expressing RapGAP1 had 40% decreased responsiveness to isoproterenol stimulation compared with myocytes transduced with a control adenovirus encoding YFP (Fig.  2B) . The resulting level of isoproterenol responsiveness is comparable with that observed for PLC⑀ Ϫ/Ϫ myocytes (3) (see Fig. 4B ). PLC⑀ Ϫ/Ϫ myocytes expressing RapGAP1 showed no further decrease in isoproterenol responsiveness (data not shown), supporting a specific role for Rap-mediated PLC⑀ activation downstream of ␤AR stimulation. As expected, RapGAP1 expression almost completely suppressed the response to cpTOME in wild-type AVMs (Fig.  2C) . Overall, these data indicate Rap activity is required for ␤AR-mediated activation of PLC⑀ and places the Epac-Rap-PLC⑀ pathway downstream of ␤AR stimulation.
The data in Figs. 1 and 2 provide strong evidence that the Epac/Rap/PLC⑀ pathway contributes to ␤AR signaling in the heart. Classically, ␤AR signaling in cardiac myocytes has been thought to rely on PKA activation. To assess relative contributions of PKA and Epac signaling to ␤AR responses, we treated isolated myocytes from either wild-type or PLC⑀ Ϫ/Ϫ mice with a selective activator of PKA, 6-Bnz-cAMP (17). 6-Bnz-cAMP treatment enhanced electrically evoked Ca 2ϩ release as expected; however, the increase was significantly lower than that produced by isoproterenol (Fig. 3A) . To further confirm the idea that a portion of the isoproterenol response is PKA-independent, AVMs were treated with H89, a PKA inhibitor that does not affect the Epac pathway (Fig. 3A) (17) . H89 treatment partially inhibited isoproterenol-dependent enhancement of evoked Ca 2ϩ release but completely blocked 6-Bnz-cAMPdependent enhancement. This indicates that H89 completely inhibits the PKA pathway but only partially inhibits the isoproterenol-dependent pathway, supporting the idea that a signaling pathway in addition to PKA activation is required to support full isoproterenol responsiveness. Importantly, H89 does not significantly inhibit the response to cpTOME and thus does not inhibit the Epac-PLC⑀ pathway. We also examined whether Epac and PKA pathways could additively reconstitute the maximal isoproterenol response. PLC⑀ ϩ/ϩ AVMs were treated with 6-Bnz-cAMP alone to activate PKA, cpTOME alone to activate Epac, or both to stimulate both pathways concomitantly. Both 6-Bnz-cAMP and cpTOME treatment alone significantly enhanced electrically evoked Ca 2ϩ release. As expected in both cases, this enhancement was less than that of isoproterenol treatment. However, co-treatment of AVMs with 6-Bnz-cAMP and cpTOME resulted in an additive enhancement of CICR equivalent to that of isoproterenol treatment (Fig. 3B) .
Based on these data, we hypothesized that the Epac/Rap/ PLC⑀ pathway acts in parallel and independent of the canonical PKA pathway following ␤AR stimulation in the heart. If this is true, the PKA pathway downstream of cAMP accumulation should be unaffected in PLC⑀ Ϫ/Ϫ myocytes. To ensure that 
PKA activity was intact in PLC⑀
Ϫ/Ϫ myocytes, freshly isolated myocytes were treated with 6-Bnz-cAMP to assess the effects on electrically evoked Ca 2ϩ transient amplitude. As expected, 6-Bnz-cAMP produced a 2.4-fold increase in Ca 2ϩ transient amplitude in PLC⑀ Ϫ/Ϫ myocytes (Fig. 3C) . Importantly, this level of responsiveness was equivalent to both maximal isoproterenol responses observed in PLC⑀ Ϫ/Ϫ myocytes (Fig. 3C ) and 6-Bnz-cAMP stimulation in PLC⑀ ϩ/ϩ myocytes (Fig. 3D) . H89 completely blocked both isoproterenol-dependent and 6Bnz-cAMP-dependent enhancement of Ca 2ϩ transients in myocytes isolated from PLC⑀ Ϫ/Ϫ mice (Fig. 3E) . A second PKA inhibitor combination of Rp-cAMPs and 8-Br-Rp-cAMPs also completely inhibited both isoproterenol-dependent and 6-BnzcAMP-dependent enhancement of Ca 2ϩ transients in PLC⑀ Ϫ/Ϫ AVMs (17) . Finally, expression of the PKA regulatory and catalytic subunits is not significantly altered in hearts isolated from PLC⑀ Ϫ/Ϫ mice (Fig. 3F) . Together, these data indicate that the PKA pathway is intact in AVMs from PLC⑀ Ϫ/Ϫ mice and is responsible for the remainder of the isoproterenol-dependent enhancement of evoked Ca 2ϩ release when the Epac/PLC⑀ pathway has been ablated in PLC⑀ Ϫ/Ϫ animals. To further confirm a role for acute PLC⑀ activity in ␤AR regulation of CICR, AVMs from PLC⑀ ϩ/ϩ mice were treated with U73122, an inhibitor of multiple PLC isoforms in intact cells (21, 22) . Acute treatment with U73122 (but not the inactive control U73343) decreased isoproterenol stimulation of evoked Ca 2ϩ transients by 50% (Fig. 4A and 4B ). U73122 did not affect either base line (data not shown) or isoproterenol stimulation of electrically evoked Ca 2ϩ release in PLC⑀ Ϫ/Ϫ myocytes, indicating that, in these experiments, the effects of U73122 were mediated specifically by the inhibition of PLC⑀ (Fig. 4B) . These data also indicate that the observed effects on ␤AR signaling are specific to PLC⑀ with no contribution from other PLC isoforms present in cardiac myocytes. Because U73122 blocks PLC-dependent inositol 1,4,5-trisphosphate (IP 3 ) production and Ca 2ϩ mobilization in cells, the data support a direct role for PLC⑀-phosphatidyl-4,5-bisphosphate hydrolytic activity in ␤AR-dependent enhancement of CICR. release, and PKA activation only partially increases Ca 2ϩ release in PLC⑀ ϩ/ϩ myocytes. Ca 2ϩ release (⌬405/485 nm) was measured following activation of ␤AR (1 M isoproterenol), PKA (300 M 6-Bnz-cAMP, 30 min pre-incubation during Indo-1/AM loading), or Epac (10 M cpTOME). PKA was inhibited with H89 (2 M). Results are the average (ϮS.E.); ***, p Ͻ 0.001; **, p Ͻ 0.01; nd, no difference one-way ANOVA, Bonferroni post-test. H89 had no effect on basal Ca 2ϩ transients. B, effects of co-treatment with 6-Bnz-cAMP (300 M, 30min) and 10 M cpTOME on electrically evoked Ca 2ϩ release in PLC⑀ ϩ/ϩ myocytes are additive and equivalent to treatment with 1 M isoproterenol. Data are pooled from 30 -60 total cells for each treatment obtained from 3 PLC⑀ ϩ/ϩ mice. Results are average (ϮS.E.); ***, p Ͻ 0.001 isoproterenol treatment versus cpTOME or 6-Bnz-cAMP treatment alone; nd, no difference, isoproterenol versus 6-Bnz-cAMP/cpTOME co-treatment and 6-Bnz-cAMP versus cpTOME treatment, one-way ANOVA, Bonferroni post-test. C, effects of 6-Bnz-cAMP (300 M, 30 min) and isoproterenol (1 M) on average (ϮS.E.) peak electrically evoked Ca 2ϩ release in PLC⑀ Ϫ/Ϫ myocytes. D, PKA activation with 6-Bnz-cAMP produced equivalent levels of enhanced CICR in PLC⑀ Ϫ/Ϫ or PLC⑀ ϩ/ϩ myocytes. Both cell types were treated with 6-Bnz-cAMP as described above. Results are average (ϮS.E.). E, Ca 2ϩ transient amplitudes from PLC⑀ Ϫ/Ϫ mice treated with 1 M isoproterenol, 300 M 6-Bnz-cAMP, 10 M H89, 350 M Rp-cAMPs, and 8-Br-Rp-cAMPs. H89, Rp-cAMPs, and 8-Br-Rp-cAMPs had no effect on base line Ca 2ϩ transients. Results are average (ϮS.E.). ***, p Ͻ 0.001, one-way ANOVA. F, cytosolic extracts (5 g) from hearts isolated from PLC⑀ Ϫ/Ϫ and PLC⑀ ϩ/ϩ mice were analyzed for expression of the regulatory and catalytic subunits of PKA. G protein ␤-subunit was assessed as a loading control.
To further support these observations, we transduced PLC⑀ Ϫ/Ϫ AVMs with PLC⑀ adenovirus. Isoproterenol-stimulated increases in Ca 2ϩ transient amplitude analyzed 24 h post-infection were enhanced ϳ3-fold over basal in the PLC⑀-expressing myocytes, similar to that observed for PLC⑀ ϩ/ϩ myocytes, compared with only a 1.5-2-fold over increase in YFP-expressing PLC⑀ Ϫ/Ϫ myocytes (Fig. 4C) . The rescue of full isoproterenol responsiveness by re-introduction of PLC⑀ in AVMs of PLC⑀ Ϫ/Ϫ mice provides compelling evidence that specific deletion of PLC⑀ was responsible for the observed reduction in ␤AR regulation of CICR.
PLC⑀-dependent changes in ␤AR-mediated stimulation of electrically evoked Ca 2ϩ release could potentially result from PLC⑀ activity enhancing SR Ca 2ϩ uptake leading to an increase in SR Ca 2ϩ load. To test whether PLC⑀ activity acting downstream of ␤AR activation alters SR Ca 2ϩ load, we assessed releasable SR Ca 2ϩ content by applying caffeine (10 mM) to maximally activate the ryanodine receptor. Peak caffeine-induced Ca 2ϩ release was not different between PLC⑀ ϩ/ϩ and PLC⑀ Ϫ/Ϫ animals (Fig. 5A) . ␤AR stimulation increases SR Ca 2ϩ load by enhancing SR Ca 2ϩ re-uptake following phosphorylation and subsequent disassociation of phospholamban from sarcoendoplasmic reticulum Ca 2ϩ -ATPases. As expected, isoproterenol treatment enhanced SR Ca 2ϩ load, and this increase was similar in AVMs obtained from both PLC⑀ ϩ/ϩ and PLC⑀ Ϫ/Ϫ mice (Fig. 5B) . Thus, ␤AR-mediated enhancement of SR Ca 2ϩ load is not altered by PLC⑀ deletion. We also assessed the aggregate activity of rapid Ca 2ϩ clearance mechanisms during excitation contraction coupling (e.g. sodium/calcium exchange and sarcoendoplasmic reticulum Ca 2ϩ -ATPase reuptake) by fitting a single exponential to the time course of Ca 2ϩ transient decay under both base line conditions and following application of isoproterenol (Fig. 5C ). Although ␤AR stimulation significantly accelerated the rate of Ca 2ϩ transient decay, no significant difference was observed between PLC⑀ ϩ/ϩ and PLC⑀ Ϫ/Ϫ myocytes (Fig. 5D ). The data in Fig. 5 demonstrate that ␤AR-mediated enhancement of SR Ca 2ϩ load and myoplasmic Ca 2ϩ clearance are not significantly altered by PLC⑀ ablation, indicating that PLC⑀ regulates the Ca 2ϩ trigger and or release process.
DISCUSSION
␤ARs enable the heart to respond to stress by increasing SR Ca 2ϩ release and thus cardiac contractility. A role for PKA-dependent phosphorylation and functional regulation of cardiac Ca 2ϩ handling proteins including L-type Ca 2ϩ channels, ryanodine receptors, and phospholamban is well documented (23, 24) . Since its discovery in 1998, Epac has been shown to also contribute to cAMP signaling in many processes once thought to depend entirely on PKA phosphorylation events (13, 25) . Our data demonstrate for the first time that cAMP-dependent activation of Epac, in addition to PKA activation, is required for maximal ␤AR stimulation of CICR in the myocardium. The data support a model where an Epac-Rap-PLC⑀ pathway acts downstream of cAMP and parallel to the PKA pathway during ␤AR stimulation (Fig. 6) . It is likely that the decreased contractile function observed in PLC⑀ null mice in response to ␤AR stimulation (3) arises from the loss of PLC⑀-dependent enhancement of Ca 2ϩ release from the SR, but this needs to be further investigated.
Although this study has characterized the upstream signaling pathway that links ␤AR stimulation to PLC⑀ activation in cardiac myocytes, the downstream targets of PLC⑀ activity in ␤AR-mediated enhancement of CICR are unknown. Acute inhibition of PLC⑀ activity with U73122 (Fig. 4) implicates PLC⑀-dependent phosphatidyl-4,5-bisphosphate hydrolysis activity, as opposed to its Rap-guanine nucleotide exchange factor activity, in the ␤AR response. PLC⑀ hydrolytic activity, as with all PLC enzymes, leads to the production of IP 3 and diacylglycerol. Knock-out of the type 2 IP 3 receptor, the predominant IP 3 receptor found in cardiac myocytes, does not affect ␤AR responsiveness in isolated atrial cardiac myocytes (26) . Based on this and other data, it appears unlikely that IP 3 generation and subsequent Ca 2ϩ release from IP 3 receptors is responsible for the observed PLC⑀-mediated increase in CICR in cardiac myocytes, although it has recently been shown that local IP 3 release can regulate cardiac hypertrophy (27) . Diacylglycerol-dependent protein kinase C activation is a more likely candidate for influencing CICR. Multiple protein kinase C isoforms are expressed in the heart, and protein kinase C stimulation exerts both positive and negative inotropic effects, depending on which isoform is stimulated (28) . Potential targets of protein kinase C include proteins that regulate Ca 2ϩ handling (L-type Ca 2ϩ channel, ryanodine receptor, phospholamban) or action potential duration (K ϩ channels) (Fig. 6) . As for PKA, there are multiple potential downstream targets of PLC⑀ that need to be thoroughly investigated before a comprehensive understanding of how PLC⑀ activity contributes to CICR and cardiac contractility can be fully appreciated.
Defining the ␤AR-mediated upstream regulation of PLC⑀ in cardiac myocytes is one important step in ongoing efforts to elucidate the mechanism of PLC⑀ action in cardiac function. The pathway outlined here is clearly important for maximal ␤AR regulation of cardiac function. Mice deficient in PLC⑀ also exhibit an increased susceptibility to cardiac hypertrophy and fibrosis (3), hallmarks of heart failure progression. However, the precise role PLC⑀ signaling plays in enhancement of CICR and PLC⑀-dependent protection from hypertrophy may be mediated by separate downstream signaling pathways. A recent report suggests a role for Epac and Rap in the suppression of cardiac hypertrophy in an ERK5-dependent manner (29) . On the other hand, other investigators suggest that chronic activation of Epac in neonatal cardiac myocyte culture promotes hypertrophy (30) . Because sympathetic regulation of cardiac function is critical for the normal response of the heart to stress, and perturbation of ␤-adrenergic signaling is one of the major contributors to progressive heart failure, determining specific roles of the Epac-Rap-PLC⑀ signaling pathway in normal and pathological cardiac function could be of important therapeutic value to heart failure patients.
